Pregnancy outcome after exposure to injectable ribavirin during embryogenesis

We describe normal pregnancy outcome in a case of first trimester exposure to injectable ribavirin in a 36-year-old pregnant woman who received three intramuscular injections of ribavirin for suspected SARS. She delivered at 40 weeks of gestation a healthy baby girl. In pediatric follow up at 8 mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Rezvani, Massoud, Koren, Gideon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2006
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134815/
https://www.ncbi.nlm.nih.gov/pubmed/16122903
http://dx.doi.org/10.1016/j.reprotox.2005.06.005
_version_ 1783517916770074624
author Rezvani, Massoud
Koren, Gideon
author_facet Rezvani, Massoud
Koren, Gideon
author_sort Rezvani, Massoud
collection PubMed
description We describe normal pregnancy outcome in a case of first trimester exposure to injectable ribavirin in a 36-year-old pregnant woman who received three intramuscular injections of ribavirin for suspected SARS. She delivered at 40 weeks of gestation a healthy baby girl. In pediatric follow up at 8 month of age, physical examination and neurodevelopmental milestones were normal.
format Online
Article
Text
id pubmed-7134815
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71348152020-04-08 Pregnancy outcome after exposure to injectable ribavirin during embryogenesis Rezvani, Massoud Koren, Gideon Reprod Toxicol Article We describe normal pregnancy outcome in a case of first trimester exposure to injectable ribavirin in a 36-year-old pregnant woman who received three intramuscular injections of ribavirin for suspected SARS. She delivered at 40 weeks of gestation a healthy baby girl. In pediatric follow up at 8 month of age, physical examination and neurodevelopmental milestones were normal. Elsevier Inc. 2006-01 2005-08-24 /pmc/articles/PMC7134815/ /pubmed/16122903 http://dx.doi.org/10.1016/j.reprotox.2005.06.005 Text en Copyright © 2005 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Rezvani, Massoud
Koren, Gideon
Pregnancy outcome after exposure to injectable ribavirin during embryogenesis
title Pregnancy outcome after exposure to injectable ribavirin during embryogenesis
title_full Pregnancy outcome after exposure to injectable ribavirin during embryogenesis
title_fullStr Pregnancy outcome after exposure to injectable ribavirin during embryogenesis
title_full_unstemmed Pregnancy outcome after exposure to injectable ribavirin during embryogenesis
title_short Pregnancy outcome after exposure to injectable ribavirin during embryogenesis
title_sort pregnancy outcome after exposure to injectable ribavirin during embryogenesis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134815/
https://www.ncbi.nlm.nih.gov/pubmed/16122903
http://dx.doi.org/10.1016/j.reprotox.2005.06.005
work_keys_str_mv AT rezvanimassoud pregnancyoutcomeafterexposuretoinjectableribavirinduringembryogenesis
AT korengideon pregnancyoutcomeafterexposuretoinjectableribavirinduringembryogenesis

Ejemplares similares